Target and Technology
SGN-LIV1A is an antibody-drug conjugate (ADC) that we are developing for the treatment of metastatic breast cancer in patients whose tumors express the LIV-1 protein. LIV-1 has limited expression in normal tissue. It combines a humanized anti-LIV-1 monoclonal antibody with the microtubule-disrupting agent monomethyl auristatin E (MMAE), using a protease-cleavable linker. LIV-1 is found in all three subtypes of breast cancer (triple negative, HER2+, and hormone-receptor positive). The MMAE is released when internalized by the target cells.
ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.
Clinical Development Status
- Phase 1 clinical trial of SGN-LIV1A for patients with LIV-1 positive metastatic breast cancer, with a focus on triple-negative breast cancer
Proposed Mechanism of Action
SGN-LIV1A is an investigational agent, and its safety and efficacy have not yet been established.